1)日本肝癌研究会,肝癌追跡調査委員会:第19回全国原発性肝癌追跡調査報告,メディア・プランニング,2014
2)Murashima S, Tanaka M, Haramaki M, et al:A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 51:808-812,2006
3)Tamura Y, Yamagiwa S, Aoki Y, et al:Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci 54:2530-2537,2009
4)Aoyagi Y, Suzuki Y, Isemura M, et al:Differential reactivity of alpha-fetoprotein with lectins and evaluation of its usefulness in the diagnosis of hepatocellular carcinoma. Gan 75:809-815,1984
5)Aoyagi Y, Suzuki Y, Isemura M, et al:The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 61:769-774,1988
6)Aoyagi Y, Isemura M, Yosizawa Z, et al:Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophys Acta 830:217-223,1985
7)Aoyagi Y, Suzuki Y, Igarashi K, et al:Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans. Br J Cancer 67:486-492,1993
8)Aoyagi Y, Isemura M, Suzuki Y, et al:Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet 2:1353-1354,1985
9)Aoyagi Y:Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Glycoconj J 12:194-199,1995
10)Taketa K, Ichikawa E, Taga H, et al:Antiboby-affinity blotting, a sensitive technique for the detection of alpha-fetoprotein separated by lectin affinity electrophoresis in agarose gels. Electrophoresis 6:492-497,1985
11)Yamashita F, Tanaka M, Satomura S, et al:Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 111:996-1001,1996
12)Aoyagi Y, Isokawa O, Suda T, et al:The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer 83:2076-2082,1998
13)Kobayashi M, Kuroiwa T, Suda T, et al:Fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to low concentrations of serum alpha-fetoprotein. Hepatol Res 37:914-922,2007
14)青柳豊,恩地森一,田中栄司,他:厚生労働科学研究費補助金(肝炎等克服緊急対策研究事業)総括研究報告書(平成18年度)AFP-L3分画および血流中癌細胞テロメラーゼを指標とした肝細胞癌のサーベイランスの有用性に関する研究,2007
15)Tamura Y, Igarashi M, Suda T, et al:Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment. Dig Dis Sci 55:2095-2101,2010
16)Aoyagi Y, Mita Y, Suda T, et al:The fucosylation index of serum alpha-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatol Res 23:287,2002
17)Liebman HA, Furie BC, Tong MJ, et al:Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310:1427-1431,1984
18)Mita Y, Aoyagi Y, Yanagi M, et al:The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 82:1643-1648,1998
19)Okuda H, Nakanishi T, Takatsu K, et al:Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 85:812-818,1999
20)Aoyagi Y, Oguro M, Yanagi M, et al:Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 77:1781-1786,1996